Pharmacogenetics of paraoxonase activity: Elucidating the role of high-density lipoprotein in disease

Pharmacogenomics

Volumn 14, Issue 12, 2013, Pages 1495-1515

  Kim, Daniel Seung ^a   Marsillach, Judit ^a   Furlong, Clement E ^a   Jarvik, Gail P ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

antioxidants; cardiovascular disease; drug interactions; gene byenvironment interactions; oxidative stress; paraoxonase; pharmacogenetics; pharmacogenomics; PON1; statins

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ARYLDIALKYLPHOSPHATASE 1; ASCORBIC ACID; ATORVASTATIN; BERBERINE; CLOPIDOGREL; ERYTHROPOIETIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCONOLACTONASE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORGANOPHOSPHATE INSECTICIDE; POLYPHENOL DERIVATIVE; PROBUCOL; QUERCETIN; RESVERATROL; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA DERIVATIVE;

AGE; ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CHOLESTEROL INTAKE; DISEASE ASSOCIATION; DISEASE MODEL; DISEASES; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ENGINEERING; GENETIC VARIABILITY; HUMAN; HYDROLYSIS; IRON INTAKE; LIFESTYLE; LIPID DIET; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PHARMACOGENETICS; POMEGRANATE JUICE; PON1 GENE; REVIEW; SEX DIFFERENCE; SMOKING; SUGAR INTAKE; XENOBIOTIC METABOLISM;

ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, HDL; NEOPLASMS; PARKINSON DISEASE; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84883869401     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.147     Document Type: Review

References (155)

1. Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: A Mendelian randomisation study. Lancet 380(9841), 572-580 (2012
2. AIM-HIGH Investigators, Boden WE, Probstfield JL et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255-2267 (2011
3. Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: A brief review. Naunyn Schmiedebergs Arch. Pharmacol. 369(1), 78-88 (2004
4. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44(16), 6371-6382 (2005
5. Ozer EA, Pezzulo A, Shih DM et al. Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing. FEMS Microbiol. Lett. 253(1), 29-37 (2005
6. Stoltz DA, Ozer EA, Ng CJ et al. Paraoxonase-2 deficiency enhances Pseudomonas aeruginosa quorum sensing in murine tracheal epithelia. Am. J. Physiol. Lung Cell Mol. Physiol. 292(4), L852-L860 (2007
7. Stevens RC, Khateeb J, Rock W et al. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning. Proc. Natl Acad. Sci. USA 105(35), 12780-12784 (2008
8. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104(1-2), 129-135 (1993
9. Furlong CE, Suzuki SM, Stevens RC et al. Human PON1, a biomarker of risk of disease and exposure. Chem. Biol. Interact. 187(1-3), 355-361 (2010
10. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: The hunt goes on. Biochem. Pharmacol. 81(3), 337-344 (2011
11. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35(6), 1126-1138 (1983
12. Furlong CE. Paraoxonases: An Historical Perspective. In: The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism. Springer, NY, USA, 3-31 (2008
13. Hassett C, Richter RJ, Humbert R et al. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: The mature protein retains its signal sequence. Biochemistry 30(42), 10141-10149 (1991
14. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52(3), 598-608 (1993
15. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3(1), 73-76 (1993
16. Li WF, Costa LG, Furlong CE. Serum paraoxonase status: A major factor in determining resistance to organophosphates. J. Toxicol. Environ. Health 40(2-3), 337-346 (1993
17. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14(3), 334-336 (1996
18. Jarvik GP, Rozek LS, Brophy VH et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler. Thromb. Vasc. Biol. 20(11), 2441-2447 (2000
19. Richter RJ, Jarvik GP, Furlong CE. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ. Cardiovasc. Genet. 1(2), 147-152 (2008
20. Richter RJ, Jarvik GP, Furlong CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol. Appl. Pharmacol. 235(1), 1-9 (2009
21. Clendenning JB, Humbert R, Green ED, Wood C, Traver D, Furlong CE. Structural organization of the human PON1 gene. Genomics 35(3), 586-589 (1996
22. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20(2), 516-521 (2000
23. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5́ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am. J. Hum. Genet. 68(6), 1428-1436 (2001
24. Suehiro T, Nakamura T, Inoue M et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150(2), 295-298 (2000
25. Kim DS, Burt AA, Ranchalis JE et al. Dietary cholesterol increases paraoxonase 1 enzyme activity. J. Lipid Res. 53(11), 2450-2458 (2012
26. Jarvik GP, Jampsa R, Richter RJ et al. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics 13(5), 291-295 (2003
27. Kim DS, Burt AA, Ranchalis JE et al. Additional common polymorphisms in the PON gene cluster predict PON1 activity but not vascular disease. J. Lipids 2012, 476316 (2012
28. Besler C, Heinrich K, Rohrer L et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest. 121(7), 2693-2708 (2011
29. Marsillach J, Martínez-Vea A, Marcas L et al. Administration of exogenous erythropoietin b affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. Clin. Exp. Pharmacol. Physiol. 34(4), 347-349 (2007
30. Marsillach J, Ferré N, Vila MC et al. Serum paraoxonase-1 in chronic alcoholics: Relationship with liver disease. Clin. Biochem. 40(9-10), 645-650 (2007
31. Parra S, Alonso-Villaverde C, Coll B et al. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis 194(1), 175-181 (2007
32. Furlong CE, Richter RJ, Li WF et al. The functional consequences of polymorphisms in the human PON1 gene. In: Proteins and Cell Regulation. Mackness B, Mackness M, Aviram M, Paragh G (Eds). Springer, The Netherlands, 267-281 (2008
33. La Du BN. Future studies of low-activity PON1 phenotype subjects may reveal how PON1 protects against cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 23(8), 1317-1318 (2003
34. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: Is the gene or the protein more important? Free Radic. Biol. Med. 37(9), 1317-1323 (2004
35. Aldridge WN. Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. Biochem. J. 53(1), 110-117 (1953
36. Aldridge WN. Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem. J. 53(1), 117-124 (1953
37. Main AR. The role of A-esterase in the acute toxicity of paraoxon, TEPP, and parathion. Can. J. Biochem. Physiol. 34(2), 197-216 (1956
38. Costa LG, McDonald BE, Murphy SD et al. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol. Appl. Pharmacol. 103(1), 66-76 (1990
39. Li WF, Furlong CE, Costa LG. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol. Lett. 76(3), 219-226 (1995
40. Shih DM, Gu L, Xia YR et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394(6690), 284-287 (1998
41. Cole TB, Walter BJ, Shih DM et al. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet. Genomics 15(8), 589-598 (2005
42. Li WF, Costa LG, Richter RJ et al. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10(9), 767-779 (2000
43. Jansen KL, Cole TB, Park SS, Furlong CE, Costa LG. Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds. Toxicol. Appl. Pharmacol. 236(2), 142-153 (2009
44. Harel M, Aharoni A, Gaidukov L et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11(5), 412-419 (2004
45. Sarkar M, Harsch CK, Matic GT et al. Solubilization and humanization of paraoxonase-1. J. Lipids 2012, 610937 (2012
46. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275(6), 3957-3962 (2000
47. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46(6), 1239-1247 (2005
48. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286(1-2), 152-154 (1991
49. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 32(4), 671-673 (1986
50. Mackness MI, Harty D, Bhatnagar D et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86(2-3), 193-199 (1991
51. Mackness B, Mackness M. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. In: Advances in Experimental Medicine and Biology. Reddy ST (Ed.). Humana Press, NY, USA, 143-151 (2010
52. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101(8), 1581-1590 (1998
53. Aviram M, Billecke S, Sorenson R et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18(10), 1617-1624 (1998
54. Watson AD, Berliner JA, Hama SY et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96(6), 2882-2891 (1995
55. Shih DM, Xia YR, Wang XP et al. Combined serum paraoxonase knockout/ apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275(23), 17527-17535 (2000
56. Tward A, Xia YR, Wang XP et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106(4), 484-490 (2002
57. Wang M, Lang X, Zou L, Huang S, Xu Z. Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: A meta-analysis based on 88 case-control studies. Atherosclerosis 214(2), 377-385 (2011
58. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: Meta-analysis of 43 studies. Lancet 363(9410), 689-695 (2004
59. Jarvik GP, Hatsukami TS, Carlson C et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler. Thromb. Vasc. Biol. 23(8), 1465-1471 (2003
60. Mackness MI, Walker CH, Carlson LA. Low A-esterase activity in serum of patients with fish-eye disease. Clin. Chem. 33(4), 587-588 (1987
61. Mackness MI, Peuchant E, Dumon MF, Walker CH, Clerc M. Absence of "A-"esterase activity in the serum of a patient with Tangier disease. Clin. Biochem. 22(6), 475-478 (1989
62. Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23(10), 1881-1888 (2003
63. Razavi AE, Ani M, Pourfarzam M, Naderi GA. Associations between high density lipoprotein mean particle size and serum paraoxonase-1 activity. J. Res. Med. Sci. 17(11), 1020-1026 (2012
64. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. 277(6), 4301-4308 (2002
65. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: Apolipoprotein A-I stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 19(9), 2214-2225 (1999
66. Deakin SP, Bioletto S, Bochaton-Piallat ML, James RW. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic. Biol. Med. 50(1), 102-109 (2011
67. Marsillach J, Mackness B, Mackness M et al. Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic. Biol. Med. 45(2), 146-157 (2008
68. Kondo I, Yamamoto M. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res. 806(2), 271-273 (1998
69. Akhmedova SN, Yakimovsky AK, Schwartz EI. Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J. Neurol. Sci. 184(2), 179-182 (2001
70. Zintzaras E, Hadjigeorgiou GM. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: A meta-analysis. J. Hum. Genet. 49(9), 474-481 (2004
71. Kelada SN, Costa-Mallen P, Checkoway H et al. Paraoxonase 1 promoter and coding region polymorphisms in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 74(4), 546-547 (2003
72. Liu YL, Yang J, Zheng J et al. Paraoxonase 1 polymorphisms L55M and Q192R were not risk factors for Parkinson's disease: A HuGE review and meta-analysis. Gene 501(2), 188-192 (2012
73. Giordano G, Tait L, Furlong CE, Cole TB, Kavanagh TJ, Costa LG. Gender differences in brain susceptibility to oxidative stress are mediated by levels of paraoxonase-2 expression. Free Radic. Biol. Med. 58, 98-108 (2013
74. Fang DH, Fan CH, Ji Q, Qi BX, Li J, Wang L. Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: Evidence from 25 published studies. Mol. Biol. Rep. 39(6), 6801-6809 (2012
75. Saadat M. Paraoxonase 1 genetic polymorphisms and susceptibility to breast cancer: A meta-analysis. Cancer Epidemiol. 36(2), e101-e103 (2012
76. Camps J, Marsillach J, Joven J. The paraoxonases: Role in human diseases and methodological difficulties in measurement. Crit. Rev. Clin. Lab. Sci. 46(2), 83-106 (2009
77. Tougou K, Nakamura A, Watanabe S, Okuyama Y, Morino A. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metab. Dispos. 26(4), 355-359 (1998
78. Biggadike K, Angell RM, Burgess CM et al. Selective plasma hydrolysis of glucocorticoid g-lactones and cyclic carbonates by the enzyme paraoxonase: An ideal plasma inactivation mechanism. J. Med. Chem. 43(1), 19-21 (2000
79. Riedmaier S, Klein K, Winter S, Hofmann U, Schwab M, Zanger UM. Paraoxonase (PON1 and PON3) polymorphisms: Impact on liver expression and atorvastatin-lactone hydrolysis. Front. Pharmacol. 2, 41 (2011
80. Bouman HJ, Schömig E, van Werkum JW et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17(1), 110-116 (2011
81. Camps J, Joven J, Mackness B et al. Paraoxonase-1 and clopidogrel efficacy. Nat. Med. 17(9), 1041-1042 (2011
82. Dansette PM, Rosi J, Bertho G, Mansuy D. Paraoxonase-1 and clopidogrel efficacy. Nat. Med. 17(9), 1040-1041; author reply 1042-1044 (2011
83. Dansette PM, Rosi J, Bertho G, Mansuy D. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem. Res. Toxicol. 25(2), 348-356 (2012
84. Tuffal G, Roy S, Lavisse M et al. An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb. Haemost. 105(4), 696-705 (2011
85. Reny JL, Combescure C, Daali Y, Fontana P, PON1 meta-analysis group. Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: A systematic review and meta-analysis. J. Thromb. Haemost. 10(7), 1242-1251 (2012
86. Ecobichon DJ, Stephens DS. Perinatal development of human blood esterases. Clin. Pharmacol. Ther. 14(1), 41-47 (1973
87. Cole TB, Jampsa RL, Walter BJ et al. Expression of human paraoxonase (PON1) during development. Pharmacogenetics 13(6), 357-364 (2003
88. Milochevitch C, Khalil A. Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging. Prostaglandins Leukot. Essent. Fatty Acids 65(5-6), 241-246 (2001
89. Wehner JM, Murphy-Erdosh C, Smolen A, Smolen TN. Genetic variation in paraoxonase activity and sensitivity to diisopropylphosphofluoridate in inbred mice. Pharmacol. Biochem. Behav. 28(2), 317-320 (1987
90. Fenkci IV, Serteser M, Fenkci S, Akyol AM. Effects of intranasal estradiol treatment on serum paraoxonase and lipids in healthy, postmenopausal women. Gynecol. Obstet. Invest. 61(4), 203-207 (2006
91. Sutherland WH, Manning PJ, de Jong SA, Allum AR, Jones SD, Williams SM. Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women. Metab. Clin. Exp. 50(3), 319-324 (2001
92. bin Ali A, Zhang Q, Lim YK, Fang D, Retnam L, Lim SK. Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. Free Radic. Biol. Med. 34(7), 824-829 (2003
93. Cheng X, Klaassen CD. Hormonal and chemical regulation of paraoxonases in mice. J. Pharmacol. Exp. Ther. 342(3), 688-695 (2012
94. Ahmad S, Scott JE. Estradiol enhances cell-associated paraoxonase 1 (PON1) activity in vitro without altering PON1 expression. Biochem. Biophys. Res. Commun. 397(3), 441-446 (2010
95. van der Gaag MS, van Tol A, Scheek LM et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 147(2), 405-410 (1999
96. Sierksma A, van der Gaag MS, van Tol A, James RW, Hendriks HF. Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol Clin. Exp. Res. 26(9), 1430-1435 (2002
97. Sarandol E, Serdar Z, Dirican M, Şafak Ö. Effects of red wine consumption on serum paraoxonase/arylesterase activities and on lipoprotein oxidizability in healthy-men. J. Nutr. Biochem. 14(9), 507-512 (2003
98. Leckey LC, Garige M, Varatharajalu R et al. Quercetin and ethanol attenuate the progression of atherosclerotic plaques with concomitant up regulation of paraoxonase1 (PON1) gene expression and PON1 activity in LDLR-/- mice. Alcohol Clin. Exp. Res. 34(9), 1535-1542 (2010
99. Rao MN, Marmillot P, Gong M et al. Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metab. Clin. Exp. 52(10), 1287-1294 (2003
100. Osaki F, Ikeda Y, Suehiro T et al. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis 176(2), 279-287 (2004
101. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem. Biophys. Res. Commun. 236(2), 289-293 (1997
102. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101(19), 2252-2257 (2000
103. Rainwater DL. Determinants of variation in serum paraoxonase enzyme activity in baboons. J. Lipid Res. 46(7), 1450-1456 (2005
104. Kudchodkar BJ, Lacko AG, Dory L, Fungwe TV. Dietary fat modulates serum paraoxonase 1 activity in rats. J. Nutr. 130(10), 2427-2433 (2000
105. Sutherland WH, Walker RJ, de Jong SA, van Rij AM, Phillips V, Walker HL. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler. Thromb. Vasc. Biol. 19(5), 1340-1347 (1999
106. de Roos NM, Schouten EG, Scheek LM, van Tol A, Katan MB. Replacement of dietary saturated fat with trans fat reduces serum paraoxonase activity in healthy men and women. Metab. Clin. Exp. 51(12), 1534-1537 (2002
107. Wallace AJ, Sutherland WH, Mann JI, Williams SM. The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes. Eur. J. Clin. Nutr. 55(11), 951-958 (2001
108. Tomás M, Sentí M, Elosua R et al. Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity. Eur. J. Pharmacol. 432(2), 121-128 (2001
109. Nguyen SD, Sok DE. Beneficial effect of oleoylated lipids on paraoxonase 1: Protection against oxidative inactivation and stabilization. Biochem. J. 375(Pt 2), 275-285 (2003
110. Mackness B, Mackness MI, Arrol S et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139(2), 341-349 (1998
111. Ikeda Y, Suehiro T, Arii K, Kumon Y, Hashimoto K. High glucose induces transactivation of the human paraoxonase 1 gene in hepatocytes. Metab. Clin. Exp. 57(12), 1725-1732 (2008
112. Nguyen SD, Hung ND, Cheon-Ho P, Ree KM, Dai-Eun S. Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1). Biochim. Biophys. Acta 1790(3), 155-160 (2009
113. Ekinci D, Beydemir S. Purification of PON1 from human serum and assessment of enzyme kinetics against metal toxicity. Biol. Trace Elem. Res. 135(1-3), 112-120 (2009
114. Li WF, Pan MH, Chung MC, Ho CK, Chuang HY. Lead exposure is associated with decreased serum paraoxonase 1 (PON1) activity and genotypes. Environ. Health Perspect. 114(8), 1233-1236 (2006
115. Gonzalvo MC, Gil F, Hernández AF, Villanueva E, Pla A. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem. Biol. Interact. 105(3), 169-179 (1997
116. Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br. J. Clin. Pharmacol. 66(3), 366-374 (2008
117. Harangi M, Mirdamadi HZ, Seres I et al. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity. Transl. Res. 153(4), 190-198 (2009
118. Kassai A, Illyés L, Mirdamadi HZ et al. The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin. Biochem. 40(1-2), 1-5 (2007
119. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: A role for sterol regulatory element-binding protein-2. Arterioscler. Thromb. Vasc. Biol. 23(11), 2083-2089 (2003
120. Dullaart RPF, de Vries R, Voorbij HAM, Sluiter WJ, van Tol A. Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in Type 2 diabetes mellitus. Eur. J. Clin. Invest. 39(3), 200-203 (2009
121. Gouédard C, Koum-Besson N, Barouki R, Morel Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol. Pharmacol. 63(4), 945-956 (2003
122. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138(2), 271-280 (1998
123. Ota K, Suehiro T, Arii K et al. Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metab. Clin. Exp. 54(2), 142-150 (2005
124. Arii K, Suehiro T, Ota K et al. Pitavastatin induces PON1 expression through p44/42 mitogen-activated protein kinase signaling cascade in Huh7 cells. Atherosclerosis 202(2), 439-445 (2009
125. Deakin S, Guernier S, James RW. Pharmacogenetic interaction between paraoxonase-1 gene promoter polymorphism C-107T and statin. Pharmacogenet. Genomics 17(6), 451-457 (2007
126. Sardo MA, Campo S, Bonaiuto M et al. Antioxidant effect of atorvastatin is independent of PON1 gene T (-107) C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Curr. Med. Res. Opin. 21(5), 777-784 (2005
127. Paragh G, Seres I, Harangi M et al. Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome. Br. J. Clin. Pharmacol. 61(6), 694-701 (2006
128. Durrington PN, Mackness MI, Bhatnagar D et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 138(1), 217-225 (1998
129. Hong SC, Zhao SP, Wu ZH. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. 47(1), 77-81 (2006
130. Turfaner N, Uzun H, Balci H et al. Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity. South Med. J. 103(5), 428-433 (2010
131. Cheng CC, Hsueh CM, Liang KW, Ting CT, Wen CL, Hsu SL. Role of JNK and c-Jun signaling pathway in regulation of human serum paraoxonase 1 gene transcription by berberine in human HepG2 cells. Eur. J. Pharmacol. 650(2-3), 519-525 (2011
132. Blatter-Garin MC, Kalix B, De Pree S, James RW. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia 46(4), 593-594 (2003
133. Jaichander P, Selvarajan K, Garelnabi M, Parthasarathy S. Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J. Lipid Res. 49(10), 2142-2148 (2008
134. Kurban S, Mehmetoglu I. Effects of acetylsalicylic acid on serum paraoxonase activity, Ox-LDL, coenzyme Q10 and other oxidative stress markers in healthy volunteers. Clin. Biochem. 43(3), 287-290 (2010
135. Noll C, Messaoudi S, Milliez P, Samuel JL, Delcayre C, Janel N. Eplerenone administration has beneficial effect on hepatic paraoxonase 1 activity in diabetic mice. Atherosclerosis 208(1), 26-27 (2010
136. van Wijk J, Coll B, Cabezas MC et al. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in Type 2 diabetic patients. Clin. Exp. Pharmacol. Physiol. 33(12), 1134-1137 (2006
137. Carreón-Torres E, Rendón-Sauer K, Monter- Garrido M et al. Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates. Clin. Chim. Acta 401(1-2), 37-41 (2009
138. Ackerman Z, Oron-Herman M, Pappo O et al. Hepatic effects of rosiglitazone in rats with the metabolic syndrome. Basic Clin. Pharmacol. Toxicol. 107(2), 663-668 (2010
139. Wójcicka G, Jamroz-Wiśniewska A, Marciniak A, Łowicka E, Bełtowski J. The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity. Life Sci. 87(3-4), 126-132 (2010
140. Aviram M, Rosenblat M, Billecke S et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26(7-8), 892-904 (1999
141. Jarvik GP, Tsai NT, McKinstry LA et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler. Thromb. Vasc. Biol. 22(8), 1329-1333 (2002
142. Tsakiris S, Karikas GA, Parthimos T, Tsakiris T, Bakogiannis C, Schulpis KH. a-tocopherolSupplementation prevents the exercise-induced reduction of serum paraoxonase 1/ arylesterase activities in healthy individuals. Eur. J. Clin. Nutr. 63(2), 215-221 (2009
143. Kunes JP, Cordero-Koning KS, Lee LH, Lynch SM. Vitamin C attenuates hypochlorite-mediated loss of paraoxonase-1 activity from human plasma. Nutr. Res. 29(2), 114-122 (2009
144. Kleemola P, Freese R, Jauhiainen M, Pahlman R, Alfthan G, Mutanen M. Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 160(2), 425-432 (2002
145. Boesch-Saadatmandi C, Egert S, Schrader C et al. Effect of quercetin on paraoxonase 1 activity - Studies in cultured cells, mice and humans. J. Physiol. Pharmacol. 61(1), 99-105 (2010
146. Gouédard C, Barouki R, Morel Y. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol. Cell. Biol. 24(12), 5209-5222 (2004
147. Gouédard C, Barouki R, Morel Y. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscler. Thromb. Vasc. Biol. 24(12), 2378-2383 (2004
148. Garige M, Gong M, Varatharajalu R, Lakshman MR. Quercetin up-regulates paraoxonase 1 gene expression via sterol regulatory element binding protein 2 that translocates from the endoplasmic reticulum to the nucleus where it specifically interacts with sterol responsive element-like sequence in paraoxonase 1 promoter in HuH7 liver cells. Metab. Clin. Exp. 59(9), 1372-1378 (2010
149. Kaplan M, Hayek T, Raz A et al. Pomegranate juiceSupplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J. Nutr. 131(8), 2082-2089 (2001
150. Aviram M, Dornfeld L, Rosenblat M et al Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: SDtudies in humans and in atherosclerotic apolipoprotein E-deficient mice Am J Clin Nutr 71(5), 1062-1076 (2000
151. Rock W, Rosenblat M, Miller-Lotan R, Levy AP, Elias M, Aviram M. Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J. Agric. Food Chem. 56(18), 8704-8713 (2008
152. Khateeb J, Gantman A, Kreitenberg AJ, Aviram M, Fuhrman B. Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: A role for PPAR-g pathway. Atherosclerosis 208(1), 119-125 (2010
153. Kim DS, Burt AA, Crosslin DR et al. Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL. J. Lipid Res. 54(2), 552-560 (2013
154. ENCODE Project Consortium. The ENCODE (ENCyclopedia of DNA elements) project. Science 306(5696), 636-640 (2004
155. Furlong CE, Richter RJ, Chapline C, Crabb JW. Purification of rabbit and human serum paraoxonase. Biochemistry 30(42), 10133-10140 (1991